Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors. Camrelizumab plus apatinib for immunochemotherapy-treated ...

Endoscopic prediction of depth of tumor invasion in early gastric cancer in the upper third of the stomach. A phase 2 study of durvalumab plus DOS (docetaxel, oxaliplatin, S-1) neoadjuvant ...

Expert Rev Anticancer Ther. 2010;10(2):221-32. Staging and risk assessment are important aspects of GIST management. Excised tumor samples should be fixed in formalin. Collection of frozen tissue ...

Gleevec shows long-term effectiveness in advanced GISTs, with complete resection and response doubling overall survival. The BFR14 study reveals a subset of patients remains progression-free at 20 ...

Gastrointestinal (GI) malignancies, including esophageal, gastric, and colorectal cancers, constitute over a quarter of newly diagnosed cancers globally and contribute significantly to cancer-related ...

The specifics of endoscopic/surgical resection and perioperative treatment ...

Gleevec remains effective in advanced GIST, with median overall survival of 75.3 months and significant long-term survival rates. Factors like female sex, gastric tumor location, smaller tumors, and ...

Changes Clinical Practice Endoscopic mucosal resection (EMR) is a welcome advance as a low-risk alternative for the management of early colonic mucosal lesions. In this multicenter, prospective ...

Please provide your email address to receive an email when new articles are posted on . Endoscopic mucosal resection followed by radiofrequency ablation had a better safety profile for managing ...